High plasma levels of oxidatively modified low-density lipoproteins are associated with the suppressed expression of immunomodulatory molecules in patients with hematological malignancies

Yang,Hai‑Qing; Qiu,Fa‑Qi; Jin,Ke; Jiang,Neng‑Gang; Zhang,Li

doi:10.3892/etm.2015.2392

High plasma levels of oxidatively modified low-density lipoproteins are associated with the suppressed expression of immunomodulatory molecules in patients with hematological malignancies

Authors:
- Hai‑Qing Yang
- Fa‑Qi Qiu
- Ke Jin
- Neng‑Gang Jiang
- Li Zhang
View Affiliations

Affiliations: Department of Hematology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China, Department of Clinical Laboratories, Ministry of Health, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: March 27, 2015 https://doi.org/10.3892/etm.2015.2392
Pages: 2394-2400

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dyslipidemia is a common feature in immunosuppressed patients, such as kidney and bone marrow transplantation recipients and patients with breast, prostate or gynecological carcinoma or acute lymphoblastic leukemia. In addition, high levels of oxidatively modified low‑density lipoproteins (oxLDLs) are closely associated with carcinogenesis. There are, however, no reports on the association between the serum oxLDL levels and the expression of important immunomodulatory molecules in patients with hematological disorders. In the present study, 39 patients with hematological disorders were stratified into four groups: Two groups with malignancies [chronic myeloid leukemia (CML) and acute myeloblastic leukemia (AML)] and two groups without malignancies [myelodysplastic syndrome (MDS) and iron deficiency anemia (IDA)]. Immunomodulatory molecules were monitored in these groups. The enzyme‑linked immunosorbent assay results indicated that the plasma oxLDL levels were significantly higher in patients with AML or CML than those in patients with MDS or IDA. The quantitative polymerase chain reaction results revealed that the expression of numerous important immunomodulatory elements, including tumor‑related genes, immunological and inflammatory cytokines, defense‑responsive genes, genes regulating cell proliferation, adhesion and migration molecules and leukocyte chemotaxis genes, showed considerable variation in patients with hematological disorders, particularly in those with MDS or IDA, as compared with the expression in the healthy volunteers. The present study demonstrated that, in patients with a hematological malignancy (either AML or CML), the activation of numerous immune response‑related molecules was inhibited. Thus, an association between hematological malignancies and dyslipidemia, i.e. high levels of oxLDL, is suggested. Further research is necessary to investigate how oxLDL influences cancer progression.

View Figures

View References

1	Chadban S, Chan M, Fry K, et al: CARI: The CARI guidelines. Nutritional management of dyslipidaemia in adult kidney transplant recipients. Nephrology (Carlton). 15:Suppl 1. S62–S67. 2010. View Article : Google Scholar : PubMed/NCBI
2	Griffith ML, Savani BN and Boord JB: Dyslipidemia after allogeneic hematopoietic stem cell transplantation: Evaluation and management. Blood. 116:1197–1204. 2010. View Article : Google Scholar : PubMed/NCBI
3	Tonkin A, Barter P, Best J, et al: National Heart Foundation of Australia; Cardiac Society of Australia and New Zealand: National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Position statement on lipid management - 2005. Heart Lung Circ. 14:275–291. 2005.PubMed/NCBI
4	Ray G and Husain SA: Role of lipids, lipoproteins and vitamins in women with breast cancer. Clin Biochem. 34:71–76. 2001. View Article : Google Scholar : PubMed/NCBI
5	Diao Y, Li H, Li H, et al: Association of serum levels of lipid and its novel constituents with the different stages of esophageal carcinoma. Lipids Health Dis. 8:482009. View Article : Google Scholar : PubMed/NCBI
6	Gottardi M, Manzato E and Gherlinzoni F: Imatinib and hyperlipidemia. N Engl J Med. 353:2722–2723. 2005. View Article : Google Scholar : PubMed/NCBI
7	Li H, Diao YT, Li HQ, et al: The association between serum levels of oxLDL-IgG and oxLDL-IgM autoantibody with adult acute myeloblastic leukaemia. Lipids Health Dis. 9:112010. View Article : Google Scholar : PubMed/NCBI
8	Bielecka-Dąbrowa A, Hannam S, Rysz J and Banach M: Malignancy-associated dyslipidemia. Open Cardiovasc Med J. 5:35–40. 2011. View Article : Google Scholar : PubMed/NCBI
9	Tatsuguchi M, Furutani M, Hinagata J, et al: Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem Biophys Res Commun. 303:247–250. 2003. View Article : Google Scholar : PubMed/NCBI
10	Chen M, Masaki T and Sawamura T: LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: Implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther. 95:89–100. 2002. View Article : Google Scholar : PubMed/NCBI
11	Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
12	Castelló IB: Hyperlipidemia: A risk factor for chronic allograft dysfunction. Kidney Int Suppl. 73–77. 2002. View Article : Google Scholar : PubMed/NCBI
13	Drüeke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A and Kreis H: Atherosclerosis and lipid disorders after renal transplantation. Kidney Int Suppl. 31:S24–S28. 1991.PubMed/NCBI
14	Mehta JL, Chen J, Hermonat PL, Romeo F and Novelli G: Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): A critical player in the development of atherosclerosis and related disorders. Cardiovasc Res. 69:36–45. 2006. View Article : Google Scholar : PubMed/NCBI
15	Silverstein DM, Palmer J, Polinsky MS, Braas C, Conley SB and Baluarte HJ: Risk factors for hyperlipidemia in long-term pediatric renal transplant recipients. Pediatr Nephrol. 14:105–110. 2000. View Article : Google Scholar : PubMed/NCBI
16	Wang Y, Li H, Diao Y, et al: Relationship between oxidized LDL antibodies and different stages of esophageal carcinoma. Arch Med Res. 39:760–767. 2008. View Article : Google Scholar : PubMed/NCBI
17	Petridou E, Mantzoros CS, Dessypris N, Dikalioti SK and Trichopoulos D: Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer. 94:156–160. 2006. View Article : Google Scholar : PubMed/NCBI
18	Chung FL, Nath RG, Ocando J, Nishikawa A and Zhang L: Deoxyguanosine adducts of t-4-hydroxy-2-nonenal are endogenous DNA lesions in rodents and humans: Detection and potential sources. Cancer Res. 60:1507–1511. 2000.PubMed/NCBI
19	Eichholzer M, Stähelin HB, Gutzwiller F, Lüdin E and Bernasconi F: Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr. 71:569–574. 2000.PubMed/NCBI
20	Iribarren C, Reed DM, Burchfiel CM and Dwyer JH: Serum total cholesterol and mortality. Confounding factors and risk modification in Japanese-American men. JAMA. 273:1926–1932. 1995. View Article : Google Scholar : PubMed/NCBI
21	Puccetti L, Pasqui AL, Bruni F, et al: Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment. Int J Cardiol. 119:41–47. 2007. View Article : Google Scholar : PubMed/NCBI
22	Uchida K: 4-Hydroxy-2-nonenal: A product and mediator of oxidative stress. Prog Lipid Res. 42:318–343. 2003. View Article : Google Scholar : PubMed/NCBI
23	Vicari AP and Caux C: Chemokines in cancer. Cytokine Growth Factor Rev. 13:143–154. 2002. View Article : Google Scholar : PubMed/NCBI
24	Guyton KZ and Kensler TW: Oxidative mechanisms in carcinogenesis. Br Med Bull. 49:523–544. 1993.PubMed/NCBI
25	Wiseman H and Halliwell B: Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. Biochem J. 313:17–29. 1996.PubMed/NCBI
26	Kelly K, Cochran BH, Stiles CD and Leder P: Cell specific regulation in normal and neoplastic cells. Adv Cancer Res. 56:1–48. 1990.
27	Oberhammer F, Bursch W, Parzefall W, et al: Effect of transforming growth factor beta on cell death of cultured rat hepatocytes. Cancer Res. 51:2478–2485. 1991.PubMed/NCBI